United States
Home
P&G Network Search
Pharmaceuticals:
US Products
Consumers:
Health Care Professionals:
FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS
CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel® (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
More:

Licensing

Contact Us




You and P&G...Think of the Possibilities

Contact our experts and we’ll do our best to contact you within two weeks.

Click on the e-mail link and follow the instructions.

Musculoskeletal Opportunities
Matthew Mull
513-622-2174
mull.mb@pg.com

Gastrointestinal Opportunities
Rick Armstrong
513-622-5473
armstrong.ra@pg.com

Women’s Health Opportunities
Julie Metz
513-622-0488
metz.ja@pg.com

Regional Opportunities in Europe
Gordon Taylor
41-58-004-7027
taylor.g.2@pg.com

Regional Opportunities in Canada
Tim Hendrickson
416-730-4236
hendrickson.t@pg.com

Explore Licensing:

Focus Areas  

Working with Us  

Current Alliances  

Contact Us  






Touching lives, improving life. P&G


©2008 Procter & Gamble. All claims valid only in the U.S.  Legal Information  Privacy Statement  P&G Links

BBBOnLine Reliability Seal